Qualigen Therapeutics (Qualigen Therapeutics) Change In Inventory : $-0.04 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Change In Inventory?

Qualigen Therapeutics's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Qualigen Therapeutics's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Qualigen Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Qualigen Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Qualigen Therapeutics's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Qualigen Therapeutics Change In Inventory Historical Data

The historical data trend for Qualigen Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Change In Inventory Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Change In Inventory

0.06

0.11

-0.64

Qualigen Therapeutics Quarterly Data
	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial													-0.20	0.07	-0.11	-	-

Qualigen Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

Qualigen Therapeutics (NAS:QLGN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Qualigen Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Qualigen Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Qualigen Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Qualigen Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

7R9:Germany

Address

2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011

Website

https://www.qualigeninc.com

Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.

Executives

Michael S. Poirier	director, officer: Chairman, President and CEO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick	director	1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger	director	100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad	officer: SVP/Chief Medical Officer	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz	officer: Vice President of Finance, CFO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David	director	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad	officer: VP, R&D, CSO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha	officer: VP of Operations	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc	10 percent owner	1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle	director	C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck	officer: Chief Financial Officer	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin	officer: VP of Finance	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino	director	C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067